BG made an arm's length exit at a 'fair' valuation when the...

BG made an arm's length exit at a 'fair' valuation when the revised clinical strategy resulted in a multi year commercialisation blow out.

JC is imitating this exit at a 'poor' valuation immediately prior to the new clinical strategy materialising because he has no nous, nor imagination.

Going to be painfully obvious in hindsight and I'd be surprised if Biosynergy ever luck themselves into this sort of opportunity ever again.

(Un)fortunately driving the Great Ocean Road today and didn't see much of the price action, but looks to have perfectly bounced of the 65EMA... who says you can't trade illiquid bios?